Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Jul 22, 2026, 5:01 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 5,081 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: HIV/AIDS Clear all
Withdrawn Phase 1 Interventional Accepts healthy volunteers

VH3739937 Phase 1 Multiple Ascending Dose (MAD) Study in Healthy Volunteers Including Relative Bioavailability (RBA), Optional Food Effect (FE), and Drug-drug Interaction (DDI)

NCT06533280
View directory record Official record
Conditions
HIV Infections
Interventions
Part A, C and D: VH3739937 500 mg, Part A: VH3739937 100 mg, Part A and C: Placebo, Part B: Treatment A, Part B: Treatment B, Part B: Treatment C, Part B: Treatment D, Part B: Treatment E, Part D: Probe cocktail
Drug
Lead sponsor
ViiV Healthcare
Industry
Eligibility
18 Years to 55 Years
Healthy volunteers
Accepts healthy volunteers
Timeline
2024
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Apr 21, 2025 · Synced Jul 22, 2026, 5:01 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Phase I, Multicenter, Randomized Trial to Evaluate the Safety and Immunogenicity of a Recombinant Vaccinia-HIV Envelope Vaccine (HIVAC-1e) in Combination With a Panel of Subunit Recombinant HIV Envelope Vaccines

NCT00000746
View directory record Official record
Conditions
HIV Infections
Interventions
rgp120/HIV-1 SF-2, Env 2-3, HIVAC-1e, gp160 Vaccine (MicroGeneSys)
Biological
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 60 Years
Enrollment
56 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
Ends 1994
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Nov 3, 2021 · Synced Jul 22, 2026, 5:01 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Phase I, Randomized, Double-Blind, Placebo-Controlled, Clinical Trial to Compare the Safety and Immunogenicity of Recombinant Envelope Protein rgp120/HIV-1SF2 (BIOCINE) Combined With Seven Adjuvants in Healthy HIV-1 Uninfected Individuals

NCT00001042
View directory record Official record
Conditions
HIV Infections
Interventions
Aluminum hydroxide, Lipid A, Monophosphoryl, Lipid A, Liposome-encapsulated monophosphoryl, Syntex adjuvant formulation, MF59, Threonyl Muramyl Dipeptide, rgp120/HIV-1 SF-2, MTP-PE/MF59
Biological
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 60 Years
Enrollment
112 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
Ends 1996
U.S. locations
3
States / cities
St Louis, Missouri • Rochester, New York • Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Nov 3, 2021 · Synced Jul 22, 2026, 5:01 PM EDT
Recruiting Not applicable Interventional

SCOPE Analytic Treatment Interruption Protocol

NCT04359186
View directory record Official record
Conditions
HIV/AIDS
Interventions
Treatment Interruption Arm
Other
Lead sponsor
University of California, San Francisco
Other
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2028
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Jan 22, 2026 · Synced Jul 22, 2026, 5:01 PM EDT
Completed Phase 3 Interventional Results available

Infrared Coagulator Ablation or Observation in Preventing Anal Cancer in HIV-Positive Patients With Anal Neoplasia

NCT01164722
View directory record Official record
Conditions
Anal Cancer, Neoplasm of Uncertain Malignant Potential, Nonneoplastic Condition, Precancerous Condition
Interventions
clinical observation, infrared photocoagulation therapy
Other · Device
Lead sponsor
AIDS Malignancy Consortium
Network
Eligibility
27 Years and older
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2016
U.S. locations
7
States / cities
Los Angeles, California • San Francisco, California • Boston, Massachusetts + 3 more
Source: ClinicalTrials.gov public record
Updated Aug 3, 2020 · Synced Jul 22, 2026, 5:01 PM EDT
Completed Phase 1 Interventional

Randomized, Phase I/II, Dose-Ranging, Open-Label Trial of the Anti-HIV Activity of Delavirdine Mesylate (DLV; U-90,152S)

NCT00000810
View directory record Official record
Conditions
HIV Infections
Interventions
Delavirdine mesylate, Zidovudine, Didanosine
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years and older
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Ends 1996
U.S. locations
10
States / cities
Stanford, California • Aurora, Colorado • Washington D.C., District of Columbia + 7 more
Source: ClinicalTrials.gov public record
Updated Nov 3, 2021 · Synced Jul 22, 2026, 5:01 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Developing Rectal USPE Measures for Suppositories (Project DRUM-S)

NCT02744261
View directory record Official record
Conditions
Microbicide Delivery System Perceptibility and Acceptability
Interventions
Gel, Suppository 1, Suppository 2
Other
Lead sponsor
The Miriam Hospital
Other
Eligibility
18 Years and older
Enrollment
32 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2022
U.S. locations
1
States / cities
Providence, Rhode Island
Source: ClinicalTrials.gov public record
Updated Feb 9, 2026 · Synced Jul 22, 2026, 5:01 PM EDT
Terminated Phase 4 Interventional Results available

Raltegravir vs. Lopinavir/Ritonavir, Both in Combination With Truvada, in HIV+ Treatment Naive Individuals

NCT00632970
View directory record Official record
Conditions
HIV Infections
Interventions
Raltegravir, Lopinavir/Ritonavir, Truvada
Drug
Lead sponsor
George Washington University
Other
Eligibility
18 Years and older
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2010
U.S. locations
1
States / cities
Washington D.C., District of Columbia
Source: ClinicalTrials.gov public record
Updated Aug 28, 2018 · Synced Jul 22, 2026, 5:01 PM EDT
Completed Not applicable Interventional

An Open-Label Study of the Safety and Efficacy of Cidofovir for the Treatment of Relapsing Cytomegalovirus Retinitis in Patients With AIDS

NCT00002142
View directory record Official record
Conditions
Cytomegalovirus Retinitis, HIV Infections
Interventions
Cidofovir, Probenecid
Drug
Lead sponsor
Gilead Sciences
Industry
Eligibility
13 Years and older
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
1
States / cities
Princeton, New Jersey
Source: ClinicalTrials.gov public record
Updated Jun 23, 2005 · Synced Jul 22, 2026, 5:01 PM EDT
Terminated Phase 2 Interventional Results available

Cardiometabolic Effects of Eplerenone in HIV Infection

NCT02629094
View directory record Official record
Conditions
Cardiac Steatosis, Hepatic Steatosis
Interventions
Inspra /Eplerenone
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 75 Years
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2017
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Jul 16, 2018 · Synced Jul 22, 2026, 5:01 PM EDT
Completed Not applicable Interventional Results available

Improving Treatment and Retention Adherence in Nontraditional Settings

NCT04973254
View directory record Official record
Conditions
HIV Infections
Interventions
CAB-RPV LA, Standard treatment within an HIV clinic
Other
Lead sponsor
Boston Medical Center
Other
Eligibility
18 Years and older
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2023
U.S. locations
2
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jan 14, 2025 · Synced Jul 22, 2026, 5:01 PM EDT
Completed Phase 3 Interventional Results available

Study to Identify and Determine Best Implementation Practices for Injectable Cabotegravir+Rilpivirine in the United States (US)

NCT04001803
View directory record Official record
Conditions
HIV Infections
Interventions
CAB LA+RPV LA
Drug
Lead sponsor
ViiV Healthcare
Industry
Eligibility
18 Years and older
Enrollment
115 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2022
U.S. locations
9
States / cities
Sacramento, California • Washington D.C., District of Columbia • Jacksonville, Florida + 6 more
Source: ClinicalTrials.gov public record
Updated Apr 13, 2023 · Synced Jul 22, 2026, 5:01 PM EDT
Completed Phase 2 Interventional

A Study of Viracept in AIDS Patients With Mycobacterium Avium Complex Disease (MAC)

NCT00002170
View directory record Official record
Conditions
Mycobacterium Avium-Intracellulare Infection, HIV Infections
Interventions
Nelfinavir mesylate
Drug
Lead sponsor
Agouron Pharmaceuticals
Industry
Eligibility
13 Years and older
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
5
States / cities
San Diego, California • Torrance, California • Chicago, Illinois + 2 more
Source: ClinicalTrials.gov public record
Updated Jun 23, 2005 · Synced Jul 22, 2026, 5:01 PM EDT
Completed Not applicable Interventional

A Study of Two Anti-HIV Drug Combinations

NCT00002203
View directory record Official record
Conditions
HIV Infections
Interventions
Lamivudine/Zidovudine, Lamivudine, Zidovudine
Drug
Lead sponsor
Glaxo Wellcome
Industry
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
6
States / cities
Beverly Hills, California • Los Angeles, California • Chapel Hill, North Carolina + 3 more
Source: ClinicalTrials.gov public record
Updated Jun 23, 2005 · Synced Jul 22, 2026, 5:01 PM EDT
Completed Not applicable Interventional

Smoking Cessation for HIV/AIDS Patients

NCT00502827
View directory record Official record
Conditions
Human Immunodeficiency Virus
Interventions
Cell Phone Intervention, Recommended Standard of Care
Behavioral · Other
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
706 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2015
U.S. locations
2
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Feb 25, 2016 · Synced Jul 22, 2026, 5:01 PM EDT
Completed Not applicable Interventional

Testing of the Integrated Rapid Access to HIV Prevention Program for People Who Inject Drugs Program

NCT04531670
View directory record Official record
Conditions
HIV Prevention Program, Opioid-use Disorder
Interventions
iRaPID, Standard of Care
Behavioral · Other
Lead sponsor
University of Connecticut
Other
Eligibility
18 Years and older
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Sep 20, 2023 · Synced Jul 22, 2026, 5:01 PM EDT
Completed No phase listed Observational Accepts healthy volunteers Results available

Prospective Cohort Study of HIV and Zika in Infants and Pregnancy

NCT03263195
View directory record Official record
Conditions
HIV, Zika Virus, Pregnant Women
Interventions
Not listed
Lead sponsor
Westat
Other
Eligibility
15 Years and older · Female only
Enrollment
395 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2020
U.S. locations
4
States / cities
Miami, Florida • The Bronx, New York • Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jan 13, 2022 · Synced Jul 22, 2026, 5:01 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

PK and Safety Study of Vaginal Rings Containing Dapivirine and Levonorgestrel

NCT02855346
View directory record Official record
Conditions
HIV Prevention
Interventions
200 mg of DPV + 320 mg LNG, 200 mg of DPV
Combination Product
Lead sponsor
International Partnership for Microbicides, Inc.
Industry
Eligibility
18 Years to 45 Years · Female only
Enrollment
24 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017
U.S. locations
2
States / cities
Birmingham, Alabama • Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated May 21, 2018 · Synced Jul 22, 2026, 5:01 PM EDT
Completed Phase 2 Interventional Results available

A Study of the Safety and Antiretroviral Activity of 3BNC117

NCT02588586
View directory record Official record
Conditions
HIV-1 Infection
Interventions
3BNC117, Antiretroviral Treatment Interruption
Drug · Other
Lead sponsor
Rockefeller University
Other
Eligibility
18 Years to 65 Years
Enrollment
17 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2018
U.S. locations
2
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jun 15, 2021 · Synced Jul 22, 2026, 5:01 PM EDT
Completed No phase listed Observational

A Comparison of Adherence Rates to Ritonavir and Its Accompanying Protease Inhibitor

NCT00432783
View directory record Official record
Conditions
HIV Infections
Interventions
Not listed
Lead sponsor
Montefiore Medical Center
Other
Eligibility
18 Years and older
Enrollment
45 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2007
U.S. locations
1
States / cities
The Bronx, New York
Source: ClinicalTrials.gov public record
Updated Apr 26, 2018 · Synced Jul 22, 2026, 5:01 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Using Multimedia Technologies to Disseminate an HIV Prevention

NCT01863537
View directory record Official record
Conditions
HIV Infection
Interventions
Multimedia Connect, Traditional Connect
Behavioral
Lead sponsor
Columbia University
Other
Eligibility
18 Years and older
Enrollment
253 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007 – 2013
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jul 30, 2013 · Synced Jul 22, 2026, 5:01 PM EDT
Not listed Not applicable Interventional Accepts healthy volunteers

Hybrid Evaluation of a Home-based HIV Pre-exposure Prophylaxis Program

NCT05856942
View directory record Official record
Conditions
HIV Prevention, Pre-exposure Prophylaxis, STI
Interventions
Health service - home-based PrEP monitoring
Other
Lead sponsor
University of Washington
Other
Eligibility
18 Years and older
Enrollment
458 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2025
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated May 9, 2024 · Synced Jul 22, 2026, 5:01 PM EDT
Completed No phase listed Observational

Eliminating Hepatitis C Virus

NCT03401697
View directory record Official record
Conditions
Hepatitis C, HIV, Type2 Diabetes
Interventions
Not listed
Lead sponsor
Icahn School of Medicine at Mount Sinai
Other
Eligibility
18 Years and older
Enrollment
52 participants
Timeline
2018 – 2021
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Mar 23, 2021 · Synced Jul 22, 2026, 5:01 PM EDT
Completed Phase 3 Interventional Results available

A Study to Evaluate Efficacy, Safety and Tolerability in Antiretroviral Therapy (ART)-Experienced Participants of at Least 50 Years of Age Living With Human Immunodeficiency Virus (HIV) With Virologic Suppression Who Switch to DTG/3TC FDC From BIC/FTC/TAF

NCT05911360
View directory record Official record
Conditions
HIV, HIV Infections
Interventions
DTG/3TC
Drug
Lead sponsor
ViiV Healthcare
Industry
Eligibility
50 Years and older
Enrollment
205 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
24
States / cities
Phoenix, Arizona • Bakersfield, California • Palm Springs, California + 21 more
Source: ClinicalTrials.gov public record
Updated Jul 8, 2026 · Synced Jul 22, 2026, 5:01 PM EDT